GET DAILY SIGNALSGinkgo Bioworks (DNA) Q3 Results Highlight Progress on Autonomous Labs
Key Takeaways
- Ginkgo Bioworks (NYSE: DNA) reported third quarter 2026 revenue of $27.7 million, slightly below the $29.4 million recorded in the same period a year earlier.
- Loss per share from continuing operations narrowed to $0.64, compared with $1.32 in the prior-year quarter, coming in ahead of consensus expectations.
- Revenue of roughly $28 million topped the consensus estimate of about $21.6 million, according to Investing.com data.
- Ginkgo announced its first autonomous lab sale to a top-tier pharmaceutical company, Novo Nordisk, a milestone in its pivot toward automated research infrastructure.
- Cash, cash equivalents, and marketable securities totaled approximately $285 million as of September 30, 2026, down from $423 million at the end of 2025.
- The company continues to operate as a single reporting segment after completing the divestiture of its Biosecurity business earlier in 2026.
Why This Quarter Matters for the Strategic Shift
Ginkgo Bioworks is navigating a clear strategic transformation, moving away from its earlier focus on cell-engineering and biosecurity toward autonomous laboratories that rely on robotics to handle what used to be manual work. The latest results provide one of the first real data points on whether this new direction is gaining commercial traction. Following the April 2026 divestiture of the Biosecurity segment, the company now reports under a single segment, which puts revenue trends, cash usage, and early signs of autonomous lab adoption front and center for investors. The sale of the first autonomous lab to Novo Nordisk signals that the concept is moving into actual contracts, while the narrower losses suggest restructuring efforts are starting to show results.
Details on the Quarter's Financial Performance
For the third quarter ended September 30, 2026, DNA posted revenue of $27.7 million, compared with $29.4 million in the year-ago period. The loss from continuing operations improved to $41.0 million from $73.4 million a year earlier, which reflects ongoing cost discipline. Loss per share from continuing operations came to $0.64 versus $1.32 in the third quarter of 2025.
These figures came in ahead of expectations. Data from Investing.com showed the company reported a third-quarter loss of $0.64 per share, beating the consensus estimate of a $1.01 loss by $0.37, while revenue of roughly $28 million exceeded the consensus forecast of about $21.6 million. Both the better-than-expected loss and revenue figures trace back to tighter cost controls and growing interest in the autonomous lab offerings.
Market Reaction and What Investors Are Focusing On
Sentiment around DNA had already been turning more constructive ahead of the report, with the stock up roughly 25% over the prior three months even though it remained down about 12% over the trailing year. The combination of the first autonomous lab sale to Novo Nordisk and an earnings beat that also exceeded revenue consensus gave the shares an additional lift and reinforced the story around the company's repositioning. Investors appear to be judging progress more on the speed of autonomous lab adoption and cash-burn management than on top-line growth alone, and this quarter supplied early indications of movement on both fronts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What to Watch Going Forward
Looking ahead, the key question is whether the Novo Nordisk autonomous lab sale can become the start of a repeatable sales pattern. The company has indicated plans to double the size of its flagship Nebula autonomous lab during 2026, and the pace of that build-out will serve as an important gauge of both demand and execution.
Cash usage stays a primary focus. Ginkgo had previously reaffirmed a full-year 2026 cash-burn target of $125 million to $150 million, and the drop in its cash balance highlights the need to stay within that range. Continued success with subleasing excess lab space and trimming fixed costs will be essential to preserving financial runway.
Finally, attention should stay on adoption of the Cloud Lab, Datapoints, and Solutions offerings, which are meant to produce revenue in the near term while building the broader platform. If demand for autonomous labs expands beyond the initial major customer, it could represent an important turning point; if uptake slows, the company's remaining cash position would come under greater scrutiny.
Using AI Tools in My Research Process
When evaluating companies like this, I often rely on Tickeron's AI Screener to quickly scan for peers and spot relevant technical or fundamental signals. The tool lets me apply filters for industry, performance metrics, and other criteria, which helps me cross-check my fundamental analysis with additional data points in a more efficient way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNA sees its Stochastic Oscillator ascending out of oversold territory
On November 04, 2026, the Stochastic Oscillator for DNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 62 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on DNA as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +18.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
DNA broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DNA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.867) is normal, around the industry mean (2.904). P/E Ratio (-2.330) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement